PhaseBio Pharmaceuticals (NASDAQ:PHAS) released its earnings results on Thursday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04), Fidelity Earnings reports. PhaseBio Pharmaceuticals had a negative net margin of 1,768.29% and a negative return on equity of 55.69%. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.35 million.
Shares of NASDAQ:PHAS opened at $3.54 on Friday. PhaseBio Pharmaceuticals has a fifty-two week low of $2.55 and a fifty-two week high of $16.65. The company has a debt-to-equity ratio of 0.12, a current ratio of 16.51 and a quick ratio of 16.52. The firm’s 50 day simple moving average is $4.11 and its 200 day simple moving average is $8.39. The company has a market capitalization of $96.43 million and a price-to-earnings ratio of -0.79.
A number of research analysts have issued reports on PHAS shares. HC Wainwright started coverage on shares of PhaseBio Pharmaceuticals in a research report on Thursday, October 3rd. They set a “buy” rating and a $18.00 target price on the stock. William Blair restated an “outperform” rating on shares of PhaseBio Pharmaceuticals in a research report on Wednesday, September 11th. Cowen restated a “buy” rating on shares of PhaseBio Pharmaceuticals in a research report on Tuesday, September 24th. Stifel Nicolaus cut their target price on shares of PhaseBio Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Finally, Zacks Investment Research downgraded shares of PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 16th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $17.56.
PhaseBio Pharmaceuticals Company Profile
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Featured Story: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.